Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination With Pembrolizumab in Chinese Patients With Advanced Solid Tumors

NCT05338580 is registered in ClinicalTrials.gov with TJ Biopharma Co., Ltd. as lead sponsor.

NCT NCT05338580
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05338580 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label Phase II Clinical Trial of TJ271 Injection in Combination With Pembrolizumab in Chinese Patients With Advanced Solid Tumors
Lead sponsor
TJ Biopharma Co., Ltd.
Phase
Phase 2
Overall status
Withdrawn
Start date
December 31, 2023
Completion date
December 31, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

first-line non-small-cell lung cancer, first-line urothelial carcinoma, second-line melanoma, second-line urothelial carcinoma